Harrow (NASDAQ:HROW) CFO Acquires $104,650.00 in Stock

Harrow, Inc. (NASDAQ:HROW) CFO Andrew Boll acquired 3,500 shares of the stock in a transaction that occurred on Thursday, May 14th. The stock was acquired at an average cost of $29.90 per share, with a total value of $104,650.00. Following the completion of the purchase, the chief financial officer owned 814,679 shares of the company’s stock, valued at $24,358,902.10. This trade represents a 0.43% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

Harrow Trading Up 3.5%

NASDAQ HROW opened at $30.86 on Friday. Harrow, Inc. has a one year low of $24.62 and a one year high of $54.85. The company has a debt-to-equity ratio of 10.30, a quick ratio of 2.06 and a current ratio of 2.48. The company has a market capitalization of $1.15 billion, a price-to-earnings ratio of -75.27 and a beta of 0.34. The company’s 50-day simple moving average is $36.67 and its two-hundred day simple moving average is $42.21.

Harrow (NASDAQ:HROW) last announced its quarterly earnings results on Monday, May 11th. The company reported ($0.74) earnings per share for the quarter, missing the consensus estimate of ($0.43) by ($0.31). The business had revenue of $44.20 million during the quarter, compared to analysts’ expectations of $52.43 million. Harrow had a positive return on equity of 19.59% and a negative net margin of 5.57%.During the same period in the previous year, the company posted ($0.38) EPS. Equities analysts forecast that Harrow, Inc. will post 0.48 EPS for the current fiscal year.

Institutional Trading of Harrow

Institutional investors have recently made changes to their positions in the business. Penn Capital Management Company LLC acquired a new position in Harrow during the 3rd quarter valued at about $15,717,000. Luxor Capital Group LP acquired a new stake in Harrow in the third quarter worth about $14,807,000. Dimensional Fund Advisors LP boosted its holdings in Harrow by 56.4% in the first quarter. Dimensional Fund Advisors LP now owns 579,520 shares of the company’s stock worth $20,428,000 after acquiring an additional 208,972 shares in the last quarter. New York State Common Retirement Fund grew its stake in shares of Harrow by 1,944.7% during the third quarter. New York State Common Retirement Fund now owns 213,789 shares of the company’s stock worth $10,300,000 after acquiring an additional 203,333 shares during the last quarter. Finally, Bank of America Corp DE grew its stake in shares of Harrow by 266.8% during the second quarter. Bank of America Corp DE now owns 213,448 shares of the company’s stock worth $6,519,000 after acquiring an additional 155,258 shares during the last quarter. Institutional investors and hedge funds own 72.76% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts have recently issued reports on HROW shares. William Blair reiterated an “outperform” rating on shares of Harrow in a report on Tuesday, March 3rd. Weiss Ratings downgraded Harrow from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Wednesday, April 22nd. Nomura lowered Harrow to a “neutral” rating in a research note on Wednesday, March 18th. HC Wainwright reiterated a “buy” rating and issued a $70.00 target price on shares of Harrow in a report on Thursday, March 19th. Finally, Zacks Research raised shares of Harrow from a “strong sell” rating to a “hold” rating in a research report on Friday, April 3rd. Eight investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, Harrow presently has an average rating of “Moderate Buy” and a consensus price target of $69.43.

Harrow Company Profile

Harrow Health, Inc (NASDAQ: HROW) is a U.S.-based commercial-stage biopharmaceutical company specializing in ophthalmic therapeutics and diagnostics. The company focuses on the development, manufacturing and distribution of proprietary, generic and branded eye care products designed to treat a range of ocular conditions, including glaucoma, ocular hypertension, dry eye disease and other anterior segment disorders.

Through its wholly owned affiliate ImprimisRx, Harrow Health offers a direct-to-physician model for customized formulations as well as low-cost generic alternatives.